International Journal of Hematology

, Volume 75, Issue 5, pp 534–539 | Cite as

Synergistic Growth Inhibition of YM529 with Biologic Response Modifiers (BRMs) in Myeloma Cells

  • Kenichiro Yata
  • Takemi Otsuki
  • Osamu Yamada
  • Hideho Wada
  • Yoshihito Yawata
  • Takashi Sugihara
Case Report

Abstract

Bisphosphonates (BPs) are effective in the management of bone disease in patients with multiple myeloma. Recent reports have suggested that they may also have an antitumor activity. YM529 is a new synthetic BP with more than 1000 times the bone resorption inhibitory activity of pamidronate. To clarify the direct effects of YM529 on myeloma cells, the cell proliferation and cell cycle perturbation were analyzed using 12 myeloma cell lines established in our laboratory. The growth inhibition was dose dependent. The cells accumulated in [2n≪4n] of the cell cycle and subsequently formed an apoptotic sub-G1 fraction. Combined treatment with all-trans retinoic acid, thalidomide, or interferon-α enhanced the growth inhibitory effects of YM529 on these cells. However, there were no remarkable effects of YM529 on the messenger RNA expression for angiogenic factors, cell cycle regulators, or cytokines related to myeloma cells. These results indicate that YM529 is beneficial not only to bone lesions but also for its direct antitumor effects on myeloma cells.

Key words

Myeloma Bisphosphonate YM529 Cell line 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Callander NS,Roodman GD. Myeloma bone disease.Semin Hematol. 2001;38:276–285.CrossRefPubMedGoogle Scholar
  2. 2.
    Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action.J Clin Invest. 1996;97:2692–2696.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.Cancer Res. 1998;58:5294–5297.PubMedGoogle Scholar
  4. 4.
    Dhodapkar MV, Singh J, Mehta J, et al. Anti-myeloma activity of pamidronate in vivo.Br J Haematol. 1998;103:530–532.CrossRefPubMedGoogle Scholar
  5. 5.
    Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.J Clin Oncol. 1998; 16:593–602.CrossRefPubMedGoogle Scholar
  6. 6.
    Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.Br J Haematol. 1997;98:665–672.CrossRefPubMedGoogle Scholar
  7. 7.
    Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.Leukemia 1998;12:220–229.CrossRefPubMedGoogle Scholar
  8. 8.
    Derenne S, Amiot M, Barille S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.J Bone Miner Res. 1999;14:2048–2056.CrossRefPubMedGoogle Scholar
  9. 9.
    Kunzmann V, Bauer E, Feurle J,Weissinger F,Tony HP,Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.Blood.2000;86:384–392.Google Scholar
  10. 10.
    Usui T, Kawakami R, Watanabe T, Higuchi S. Sensitive determination of a novel bisphosphonate, YM529, in plasma, urine and bone by high-performance liquid chromatography with fluorescence detection.J Chromatogr. 1994;652:67–72.CrossRefPubMedGoogle Scholar
  11. 11.
    Sasaki A, Kitamura K, Alcalde RE, et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.Int J Cancer. 1998;77:279–285.CrossRefPubMedGoogle Scholar
  12. 12.
    Takahashi R, Shimazaki C, Inaba T, et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.Leuk Res. 2001;25:77–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Tassone P, Forciniti S, Gallea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines.Leukemia. 2000;14:841–844.CrossRefPubMedGoogle Scholar
  14. 14.
    Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.Br J Cancer.2001;84:1126–1134.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Musto P, Sajeva MR, Sanpaolo G, DArena G, Scalzulli PR, Carotenuto M. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma.Haematologica. 1997;82:354–356.PubMedGoogle Scholar
  16. 16.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma.N Engl J Med. 1999;341:1565–1571.CrossRefPubMedGoogle Scholar
  17. 17.
    Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.Br J Haematol. 2001;113: 1020–1034.CrossRefGoogle Scholar
  18. 18.
    Otsuki T, Yamada O, Yata K, et al. Genetic and biological characterization of human myeloma cell lines: an overview of the lines established at Kawasaki Medical School.Gene Funct Dis. 2000;1:48–56.CrossRefGoogle Scholar
  19. 19.
    Otsuki T, Yamada O, Sakaguchi H,et al. Human myeloma cell apoptosis induced by interferon-α.Br J Haematol. 1998;103:518–529.CrossRefPubMedGoogle Scholar
  20. 20.
    Otsuki T, Yata K, Sakaguchi H, et al. IL-10 abolishes the growth inhibitory effects of all trans retinoic acid (ATRA) on human myeloma cells.Br J Haematol. 2002;116:787–795.CrossRefPubMedGoogle Scholar
  21. 21.
    Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000;96:2943–2950.PubMedGoogle Scholar
  22. 22.
    Berger LC, Hawley RG. Interferon-beta interrupts interleukin-6-dependent signaling events in myeloma cells.Blood. 1997;89: 261–271.PubMedGoogle Scholar
  23. 23.
    Tanaka K, Otsuki T, Sonoo H, et al. Semi-quantitative comparison of the differentiation markers and sodium iodide symporter in papillary thyroid carcinomas using RT-PCR method.Eur J Endocrinol. 2000;142:340–346.CrossRefPubMedGoogle Scholar
  24. 24.
    Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultra-structure.J Clin Invest. 1991;88:2095–2105.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000;96:2943–2950.PubMedGoogle Scholar
  26. 26.
    Chen YH, Lavelle D, DeSimone J, Uddin S, Platanias LC, Hankewych M. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21 (WAF1).Blood. 1999;94:251–259.PubMedGoogle Scholar
  27. 27.
    Dallas SL, Garrett IR, Oyajobi BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.Blood. 1999;93:1697–1706.PubMedGoogle Scholar
  28. 28.
    Shipman CM, Vanderkerken K, Rogers MJ, et al. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.Br J Haematol. 2000;111:283–286.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Kenichiro Yata
    • 1
  • Takemi Otsuki
    • 2
  • Osamu Yamada
    • 1
  • Hideho Wada
    • 1
  • Yoshihito Yawata
    • 3
  • Takashi Sugihara
    • 1
  1. 1.Division of Hematology, Department of Internal MedicineKawasaki Medical SchoolOkayamaJapan
  2. 2.Department of HygieneKawasaki Medical SchoolJapan
  3. 3.Department of Care WorkKawasaki College of Allied Health ProfessionsOkayamaJapan

Personalised recommendations